<DOC>
	<DOCNO>NCT02793661</DOCNO>
	<brief_summary>The Strength study aim evaluate use RenalGuard device protect patient high risk develop acute kidney injury follow complex cardiovascular intervention require high volume contrast .</brief_summary>
	<brief_title>Study Evaluate Use RenalGuard Protect Patients High Risk AKI</brief_title>
	<detailed_description>The Strength Trial randomize , international ( France Germany ) multicentre ( 7 ) trial . The patient population target suffer kidney insufficiency ( estimate Glomerular Filtration Rate ( eGFR ) 15 40 ml/min/m2 ) need go complex cardiovascular intervention.. This population patient high risk develop AKI follow contrast medium administration complex cardiovascular intervention require high amount contrast . Standard treatment hydration risk hyper hypohydration population patient . RenalGuard insure replacement urine output infusion match volume sterile replacement solution maintain patient ' intravascular fluid volume . The patient randomize protected contrast-induced nephropathy use RenalGuard standard hydration treatment followed-up 12 month .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>Age &gt; 18 year old 15 ml/min/m2 ≤ eGFR ≤ 40 ml/min/m2 High volume contrastrequiring cardiovascular procedure ( estimate contrast volume &gt; 3 time eGFR value ) Patient agree FU test Administration iodine contrast medium within 5 day index procedure Emergency procedure primary PCI Patients pulmonary edema cardiogenic shock ( Killip 3 4 ) Hypoxemia define SaO2 ≤ 90 % and/or PaO2 ≤ 80 mmHg room air Acute Kidney Injury require dialysis procedure Multiple myeloma cancer treat chemotherapy Subjet anuric Subject hospitalize change renal function undergone renal replacement therapy ( hemodialysis hemofiltration ) within past month Known hypersensitivity furosemide active ingredient excipient Renal insufficiency oligoanuria resistant furosemide cause nephrotoxic hepatotoxic substance Precoma coma induce hepatic encephalopathy Severe hypokalemia , sever hyponatremia , hypovolemia without hypotension dehydration Hypersensitivity sulfamides Enrollment another study unless study registry unless primary endpoint reach Expected life expectancy &lt; 1 year Pregnant breastfeeding patient Patient trusteeship guardianship Patient unable / unwilling provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>